Jin Medical International Ltd. (ZJYL) Cash Flow Statement
Where ZJYL’s cash came from and went, FY2025
September 30, 2025 · U.S. dollars- Cash from operations
- $2.9M
- Capital expenditures
- $6.6M 32.0% of revenue
- Free cash flow
- −$3.7M −18.0% margin
- Returned to shareholders
- —
- Change in cash
- −$674,549 cash at year-end $7.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
ZJYL operating cash flow, capex and free cash flow
ZJYL cash flow trends, FY2018–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$2.4MFY2018 | $2.9MFY2025 | — | |
| Capital expenditures | $187,679FY2018 | $6.6MFY2025 | +66.4%/yr | |
| Free cash flow | −$2.6MFY2018 | −$3.7MFY2025 | — | |
| Free cash flow margin | −12.3%FY2018 | −18.0%FY2025 | −5.7 pts | |
| Operating cash flow / net income | −0.65FY2018 | 2.10FY2025 | +2.75 | |
| Stock-based compensation | −$5.4MFY2019 | −$95,339FY2021 | — | |
| Capex / revenue | 0.9%FY2018 | 32.0%FY2025 | +31.2 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ZJYL cash flow by activity
ZJYL net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ZJYL cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net income | $1.4M | $3.4M | $2.9M | $2.7M | $2.6M | $2.2M | $3.6M | $3.7M |
| Depreciation & amortization | $350,679 | $346,132 | $225,902 | $362,597 | $346,608 | $329,907 | $344,036 | $368,263 |
| Stock-based compensation | — | — | — | — | −$95,339 | — | −$5.4M | — |
| Change in working capital | $1.1M | −$4.9M | −$200,810 | −$1.4M | $3.0M | −$34,856 | −$5.3M | −$7.0M |
| Other non-cash items | $75,911 | −$53,600 | $203,081 | −$57,080 | $2,368 | $2,130 | $5.4M | $569,692 |
| Cash from operating activities | $2.9M | −$1.2M | $3.1M | $1.6M | $5.8M | $2.5M | −$1.3M | −$2.4M |
| Investing activities | ||||||||
| Capital expenditures | −$6.6M | −$1.1M | −$113,937 | −$40,166 | −$42,881 | −$142,319 | −$73,328 | −$187,679 |
| Investments (net) | −$3.7M | −$9.5M | −$7.6M | −$120,904 | −$1.1M | −$2.0M | $145,419 | — |
| Acquisitions & other investing | −$499,556 | $1.1M | — | $40,166 | $42,881 | $142,319 | $54,846 | $2.1M |
| Cash from investing activities | −$10.8M | −$9.5M | — | −$120,904 | −$1.1M | −$2.0M | $126,937 | $2.0M |
| Financing activities | ||||||||
| Net borrowing (repayment) | $7.6M | $6.9M | $4.3M | $121,855 | −$2.9M | −$343,907 | $2.4M | — |
| Shares issued | $0 | $311,995 | $8.0M | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$237,877 | $4.5M | −$5.3M | $0 | $0 | $0 | $0 | −$3.2M |
| Cash from financing activities | $7.4M | $11.7M | $6.9M | $121,855 | −$2.9M | −$343,907 | $2.4M | −$3.2M |
| Summary | ||||||||
| Net change in cash | −$674,549 | $1.2M | $2.1M | $1.1M | $2.0M | −$278,445 | $1.1M | −$3.6M |
| Cash at end of period | $7.5M | $8.1M | $6.9M | $4.8M | $3.7M | $1.7M | $1.9M | $853,304 |
| Free cash flow | −$3.7M | −$2.3M | $3.0M | $1.5M | $5.8M | $2.4M | −$1.4M | −$2.6M |
| Free cash flow margin | −18.0% | −9.9% | 15.1% | 8.0% | 27.9% | 14.6% | −6.9% | −12.3% |
| Capex / revenue | 32.0% | 4.8% | 0.6% | 0.2% | 0.2% | 0.9% | 0.4% | 0.9% |
| Operating cash flow / net income | 2.10 | −0.35 | 1.08 | 0.58 | 2.22 | 1.13 | −0.36 | −0.65 |
| Jun '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$107,735 | $1.3M | −$44,504 | −$89,008 | −$44,504 | $1.9M | $940,917 | $1.8M | $897,047 | $1.1M | $555,941 | $1.8M |
| Depreciation & amortization | $163,911 | $135,155 | $101,655 | $189,528 | $101,655 | $167,404 | $88,990 | $168,152 | $84,076 | $108,987 | $55,718 | $114,464 |
| Stock-based compensation | — | — | — | — | — | — | — | — | — | — | $467,388 | — |
| Change in working capital | −$492,099 | −$1.3M | $1.5M | $3.1M | $1.5M | −$3.6M | −$1.8M | −$1.6M | −$801,632 | −$822,885 | $17,131 | $361,040 |
| Other non-cash items | −$498,499 | $216,918 | $970,595 | $2.0M | −$310,419 | $266,564 | $127,994 | −$308,984 | −$154,492 | −$35,075 | −$914,723 | $501,642 |
| Cash from operating activities | −$934,422 | $341,554 | $2.6M | $5.1M | $1.3M | −$1.3M | −$628,652 | $49,998 | $24,999 | $362,910 | $181,455 | $2.7M |
| Investing activities | ||||||||||||
| Capital expenditures | −$1.8M | −$4.6M | −$1.0M | −$2.1M | −$1.0M | −$61,270 | −$30,635 | −$83,680 | −$41,840 | −$102,923 | −$51,462 | −$11,014 |
| Investments (net) | — | — | — | — | — | — | — | — | — | — | — | −$1.2M |
| Acquisitions & other investing | $2.0M | −$2.0M | −$3.2M | −$6.3M | −$1.1M | −$5.3M | −$2.7M | −$4.1M | −$2.0M | −$553,496 | −$276,747 | −$5.9M |
| Cash from investing activities | $222,008 | −$6.6M | −$4.2M | −$8.4M | −$2.1M | −$5.4M | −$2.7M | −$4.1M | −$2.1M | −$656,419 | −$328,209 | −$7.1M |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | — | — | — | — | — | — | — | — | — | $656,334 |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $2.1M | $2.5M | $4.9M | $9.8M | $2.5M | $5.7M | $2.8M | $6.0M | $3.0M | −$1.2M | −$594,634 | $7.4M |
| Cash from financing activities | $2.1M | $2.5M | $4.9M | $9.8M | $2.5M | $5.7M | $2.8M | $6.0M | $3.0M | −$1.2M | −$594,634 | $8.1M |
| Summary | ||||||||||||
| Net change in cash | $1.6M | −$3.7M | $3.0M | $3.0M | −$738,723 | −$8.9M | −$8.9M | $972,698 | $972,698 | −$1.8M | −$9.6M | $8.7M |
| Cash at end of period | $9.1M | $7.5M | $11.1M | $11.1M | $8.1M | $8.1M | $8.9M | $972,698 | $972,698 | $6.9M | −$877,339 | $8.7M |
| Free cash flow | −$2.7M | −$4.2M | $255,448 | $510,896 | $255,448 | −$1.3M | −$659,287 | −$33,682 | −$16,841 | $259,987 | $129,993 | $2.7M |
| Free cash flow margin | −30.5% | −39.2% | 5.2% | 5.2% | 5.2% | −10.2% | −10.2% | −0.3% | −0.3% | 2.7% | 2.7% | 26.7% |
| Capex / revenue | 20.0% | 42.4% | 20.8% | 20.8% | 20.8% | 0.5% | 0.5% | 0.8% | 0.8% | 1.1% | 1.1% | 0.1% |
| Operating cash flow / net income | — | 0.27 | — | — | — | −0.67 | −0.67 | 0.03 | 0.03 | 0.33 | 0.33 | 1.55 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ZJYL cash generation
In fiscal 2025 (ended September 30, 2025), Jin Medical International generated $2.9 million of cash from operations and spent $6.6 million on capital expenditures, leaving free cash flow of -$3.7 million, −18.0% of revenue. Cash and equivalents fell by $0.7 million over the year.
Related: ZJYL income statement, ZJYL balance sheet. See the ZJYL stock overview for the latest quote and news.
ZJYL cash flow FAQ
What is Jin Medical International's free cash flow?
Jin Medical International's free cash flow was -$3.7 million in fiscal 2025: $2.9 million of operating cash flow minus $6.6 million of capital expenditures It was -$2.3 million a year earlier..
How much cash does Jin Medical International generate from operations?
Jin Medical International generated $2.9 million of cash from operating activities in fiscal 2025, 2.10 times its net income of $1.4 million.
How much does Jin Medical International spend on capital expenditures?
Jin Medical International spent $6.6 million on capital expenditures in fiscal 2025, 32.0% of revenue, compared with $1.1 million the year before.